In this article, the implications of the findings from these recent studies are discussed and the critical evidence gaps that remain to be addressed are highlighted.
Introduction
Iron deficiency anaemia is a common and clinically important concern in patients with chronic kidney disease (CKD). In this patient population, chronic inflammation may lead to increased hepcidin production, in turn inhibiting both the uptake of dietary iron and the mobilization of stored iron from the reticuloendothelial system to circulating transferrin [1] . Insufficient dietary iron uptake may be compounded by poor appetite or dietary restrictions, and intestinal bleeding may result in increased iron losses [2] [3] [4] . The problem is exacerbated in patients receiving dialysis who experience significant additional iron losses due to blood remaining in the dialyser circuit after treatment. Patients with CKD receiving treatment with erythropoiesis-stimulating agents (ESAs) are very prone to iron deficiency due to the increased demand for iron to support erythropoiesis, and indeed iron deficiency is the most commonly identified cause of hyporesponsiveness to ESA therapy in dialysis patients [5, 6] . As a result, iron therapy, either alone or in combination with ESA treatment, has been an important component of the management of anaemia in patients with CKD for many years.
The chapter in this supplement authored by Berns provides a detailed discussion of the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommendations for the use of iron to treat anaemia in CKD, while the chapter by Roger discusses current opinion regarding the application of the guideline in clinical practice. Both of these chapters highlight the fact that the quality of clinical evidence underpinning the guideline recommendations is relatively poor, with the result that different interpretations are possible. In the 4 years since the publication of the guideline, several new randomized controlled trials (RCTs) have been completed, most notably the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) [7, 8] and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) [9] studies, while another large RCT, Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL), is currently in progress. In addition, a number of relevant observational studies have been published. The aim of this chapter is to summarize the findings from these more recent studies and evaluate their implications for the management of iron deficiency anaemia in patients with CKD.
Iron therapy in patients with CKD: the evidence base for the 2012 KDIGO guideline
The 2012 KDIGO guideline recommends considering a trial of intravenous (IV) or oral iron in patients with CKD for whom an increase in haemoglobin levels without starting ESA therapy is desired (or when a decrease in the current ESA dose is desired), if transferrin saturation (TSAT) levels are 30% and serum ferritin levels are 500 mg/L. In patients with non-dialysisdependent CKD (CKD-ND), it is suggested that the selection of iron administration route (oral versus IV) should be made based on the severity of anaemia, availability of venous access, response or lack of response to prior oral iron therapy, previously observed adverse events (AEs), patient adherence and cost; in patients with end-stage CKD (CKD-5D) receiving regular dialysis, oral iron is not recommended.
The recommendation to use IV rather than oral iron in CKD-5D patients was supported by a number of clinical studies in both haemodialysis and peritoneal dialysis patients (although the number of studies in peritoneal dialysis patients is very low), demonstrating a greater haemoglobin response with IV iron compared with oral iron [10] [11] [12] [13] [14] [15] . Moreover, iron therapy, and in particular IV iron therapy, was found to improve the response to ESA treatment and reduce ESA requirements in this patient population [10, 11, 13, [15] [16] [17] [18] [19] [20] [21] . At the time of guideline publication, data showing greater efficacy of IV iron compared with oral iron with respect to erythropoietic response in patients with CKD-ND were more limited [22] [23] [24] [25] [26] [27] [28] . In both patient populations, the studies on which guideline recommendations were based were generally very short in duration and involved only small numbers of patients such that no conclusions could be drawn with respect to long-term efficacy or safety of IV versus oral iron.
At the time the guidelines were written, very little clinical evidence existed to support the suggested upper limits for iron status targets [29] . The recommendation to discontinue IV iron therapy in patients with a serum ferritin >500 mg/L was based mainly on the reported potential for hepatic deposition of iron at higher ferritin levels, as well as the potential for exacerbation of oxidative stress or infections [30] [31] [32] . While serum ferritin and TSAT are the favoured markers for assessing iron status, serum ferritin is an acute-phase reactant and levels may be elevated if inflammation is present. Furthermore, hepcidinmediated blockade of iron mobilization from the reticuloendothelial system may also contribute to circumstances where patients have elevated serum ferritin levels but low TSAT. Results from the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study suggested that iron therapy may lead to increases in haemoglobin levels and reduced ESA requirements even in patients with serum ferritin levels in excess of 500 mg/L [20, 33] . However, the study was conducted in only 134 dialysis patients, and the initial period of follow-up was only 6 weeks, with a further 6-week observational extension (DRIVE-II). Clearly, the long-term safety of IV iron administration in patients with elevated serum ferritin could not be ascertained from such a short follow-up period.
Observational data on the safety of iron therapy that were available at the time of guideline publication (but not considered by the panel when making recommendations) were also conflicting: one large US study showed no increase in dialysis patient mortality with iron doses of 1000 mg over 6 months [34] , while a second study showed an increase in mortality in dialysis patients receiving doses of >400 mg/month [35] .
New evidence: the FIND-CKD and REVOKE trials
Since the publication of the KDIGO guideline, several new studies have added to the clinical evidence base in support of the efficacy and short-term safety of IV iron therapy in patients with CKD-ND and CKD-5D [36] [37] [38] [39] . A recent meta-analysis by Shepshelovich et al. [40] , updating their original 2008 analysis [41] , assessed data from 24 RCTs-13 of patients with CKD-ND and 11 of patients with CKD-5D-and concluded that patients treated with IV iron were more likely to achieve a haemoglobin increase of >1 g/dL than patients treated with oral iron (risk ratios 1.61 and 2.14 for CKD-ND and CKD-5D, respectively). Rates of mortality and serious AEs (SAEs)/AEs were found to be similar for the IV and oral iron groups, although IV iron administration was associated with a higher risk of hypotension but fewer gastrointestinal AEs. Similarly, in a meta-analysis of RCTs that evaluated IV iron for any clinical indication, treatment with IV iron was not found to be associated with increased risk of SAEs or infections versus comparator (placebo, no iron, oral iron or intramuscular iron), although the median follow-up time for the 103 studies assessed was only 8 weeks [42] (Table 1) .
Two recent studies that were designed to inform with respect to the long-term efficacy and safety of IV iron in patients with CKD-ND were the FIND-CKD and REVOKE trials. FIND-CKD, published in 2014 [8] , was designed to evaluate the efficacy of oral or IV iron (ferric carboxymaltose) to delay the onset of, or reduce the use of, ESA or other anaemia management in patients with CKD-ND and iron-deficiency anaemia when using targeted ferritin levels to determine iron dosing. A total of 626 patients across 193 sites in 20 countries were randomized to receive either high-dose IV ferric carboxymaltose (1000 mg every 4 weeks) targeting ferritin 400-600 mg/L, low-dose IV ferric carboxymaltose (200 mg every 4 weeks) targeting ferritin 100-200 mg/L, or oral iron (200 mg daily), and were followed over 56 weeks. The primary endpoint of the study was initiation of other anaemia management (ESA, other iron therapy, transfusion) or two consecutive haemoglobin measurements <10 g/dL during weeks 8-52. This endpoint occurred in 23.5, 32.2 and 31.8% of patients in the high-ferritin ferric carboxymaltose, low-ferritin ferric carboxymaltose and oral iron groups, respectively. The difference between the high-ferritin ferric carboxymaltose and oral iron groups was statistically significant [hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.44-0.95; P ¼ 0.025]. The increase in mean haemoglobin level from baseline to month 12 was significantly greater for the high-ferritin ferric carboxymaltose group versus the oral iron group, and the haematological response was also faster. Quality of life (QOL), as measured by the SF-36 instrument, did not show significant differences across groups, and AE and SAE rates were similar in all groups.
The primary objective of the REVOKE trial published 2015 [9] was to evaluate the effects of oral or IV iron on kidney function in patients with CKD-ND (stage 3/4) and iron-deficiency anaemia. A total of 136 subjects at a single centre in the USA were randomized to receive open label oral ferrous sulphate (325 mg tablets containing 65 mg elemental iron, three times daily for 8 weeks; n ¼ 69) or IV iron sucrose (200 mg every 2 weeks for total of 1 g; n ¼ 67); patients were followed for 2 years. No difference in the rate of measured glomerular filtration rate (mGFR) decline between groups was observed-i.e. IV iron was not found to accelerate (or delay) a decline in kidney function; statistically significant improvements in haemoglobin that were sustained for 24 months were observed for both the IV and oral iron groups with no significant between-group differences. However, a higher risk of SAEs [adjusted incidence rate ratio (aIRR), 1.60; 95% CI 1.28-2.00; P < 0.0001], cardiovascular (CV) SAEs (aIRR, 2.51; 95% CI 1.56-4.04; P < 0.001) and infection resulting in hospitalization (aIRR, 2.12; 95% CI 1.24-3.64; P < 0.006) in the IV iron group resulted in early termination of the study. While both of these studies represent a significant advance over previous RCTs in that they involved larger numbers of patients and much longer follow-up periods, the findings were starkly contrasting, with the authors drawing essentially opposing conclusions. The investigators of the REVOKE trial concluded that use of IV iron resulted in elevated risk of infection and CV complications and that in patients with CKD-ND, oral iron may be the preferred first-line treatment for iron deficiency anaemia. In contrast, the FIND-CKD investigators concluded that the use of IV iron to target higher ferritin levels may contribute to improved anaemia management in this patient population, with no safety concerns in terms of CV events or infectious episodes [45] .
Potential explanations for the differences in findings from these studies have been discussed in several commentaries [46] [47] [48] . One key difference between the two trials is that the dose of oral iron used in the FIND-CKD study was significantly lower than that used in the REVOKE study; this could potentially explain the conflicting conclusions drawn with respect to the efficacy of IV versus oral iron, but would not explain the discrepancy in the safety data. Another point of contention that may have bearing on the interpretation of findings is the appropriateness of adjustments for baseline patient differences that were applied in the analysis of data from the REVOKE study, particularly as some of the key safety findings only achieved statistical significance following such adjustment. In addition, the reporting and methods of adjudication of AEs differ between the two studies, further complicating their comparison. However, a recent post-hoc analysis of data from FIND-CKD examining the incidence of AEs using the same approach as the REVOKE analysis-counting individual AEs as separate events when a patient experienced multiple events-also showed no difference between treatment groups [45] . Other, more fundamental differences between the two studies include the fact that they used different iron formulations (iron sucrose versus ferric carboxymaltose) and were undertaken in different countries (USA versus multiple European countries/Australia).
New evidence: observational studies
In addition to the data from RCTs, a number of epidemiologic analyses pertaining to IV iron safety and efficacy have been published in the years since the release of the KDIGO guideline. An important consideration when interpreting findings from observational studies is that, by nature, such studies may be subject to confounding for various reasons, the most obvious in this case being that it is often the sickest patients who are given the greatest amounts of IV iron. Nonetheless, such studies can still provide insights into anaemia management trends as well as the efficacy and safety of IV iron therapy as applied in realworld clinical practice (Table 2 ).
An analysis of data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) collected between 2002 and 2011, and considering 32 435 patients in 12 countries, showed an association (albeit fairly weak) between high IV iron dose and mortality [52] . Compared with patients receiving 100-199 mg/ month, mortality was higher for those receiving 300-399 mg/ month (HR, 1.13; 95% CI 1.00-1.27) and 400þ mg/month (HR, 1.18; 95% CI 1.07-1.30). Associations with cause-specific mortality (CV, infection, other) followed a similar pattern, and receipt of 300 mg/month or more was also associated with increased risk of hospitalization (HR, 1.12; 95% CI 1.07-1.18) versus 100-199 mg/ month. In contrast, results of an analysis of data from the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE)-ESRD study considering 14 078 patients initiating dialysis between 2003 and 2008 showed no association between receipt of cumulative doses <1050 mg in 3 months or <2100 mg in 6 months with all-cause, CV or infection-related mortality [58] . A second analysis of data from the DEcIDE-ESRD study also showed no association between iron dose level during 1-, 3-or 6-month exposure windows and risk of all-cause hospitalization or death among a cohort of incident haemodialysis patients (n ¼ 9544) [56] . Several studies have examined outcomes in patients receiving bolus versus maintenance IV iron dosing. Notably, Brookhart et al.
showed that among 117 050 Medicare patients dialysing at a large dialysis organization, bolus dosing (!100 mg iron in at least two consecutive dialysis sessions and total dose with potential to exceed 600 mg within 30 days) was associated with a small increase in relative risk of infection-related hospitalizations compared with maintenance dosing, resulting in 25 additional events per 1000 patient-years [61] ; this association was found to be most pronounced in patients dialysing with a central venous catheter. Similar results were obtained in a study of 6605 patients of a small dialysis organization in which bolus dosing during a 1-month exposure period was found to be associated with a significant increase in relative risk of hospitalization for infection and receipt of IV antibiotics in the following 3 months; again associations were more pronounced in patients dialysing with catheters [57] . Infection risk associated with IV iron therapy was also assessed in a recent study of United States Renal Data System (USRDS) data: among a cohort of Medicare beneficiaries on incentre haemodialysis who received IV iron in the 14 days prior to a hospitalization for bacterial infection, no association was observed between receipt of IV iron at any point during the hospitalization and 30-day mortality, mean length of hospital stay or a composite measure of readmission for infection or death within 30 days of discharge [53] . The authors of the study concluded that their findings did not support the withholding of IV iron upon hospitalization for bacterial infection, although they noted that the majority of IV iron administered was received on the day of admission, limiting the ability to draw conclusions about the longer-term use of IV iron during the course of infection.
Observational analyses of outcomes in CKD-ND patients have suggested potential benefits of initiating IV iron therapy prior to dialysis onset. One prospective study found that CKD-ND patients who were treated with ESA and also initiated IV iron supplementation had a lower risk of all-cause death than those who did not receive iron [55] . In this study, the risk of hospitalizations was also lower, although the risk of faster progression to end-stage renal disease (ESRD) was higher. Similarly, a small retrospective study of 102 patients initiating dialysis showed that those who received IV iron and ESA prior to onset of dialysis had higher haemoglobin levels and greater left ventricular ejection fraction at the time of dialysis initiation than patients who received oral iron and ESA therapy [65] .
In summary, findings from observational studies have also been equivocal with respect to the long-term safety of IV iron (in particular, mortality and infection risk). While the differing findings may well be explained by differences in study design and patient populations assessed, the lack of a clear consensus again emphasizes the need for additional clinical data.
Future prospects: the Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL) trial
One ongoing study that may prove to be informative is the PIVOTAL trial (EudraCT number 2013-002267-25). This study is the first to assess the long-term safety and efficacy of the currently accepted practices of liberal IV iron use in patients with CKD-5D. The specific objective of the study is to compare proactive high-dose and reactive low-dose IV iron regimens with respect to all-cause mortality and incidence of non-fatal CV endpoints as well as ESA dose requirements, the need for transfusions, incidence of infections and other complications of haemodialysis and indicators of QOL. The trial is a multicentre, prospective, open-label, two-arm RCT, enrolling 2080 haemodialysis patients (new to dialysis, or on dialysis for <12 months) at 50 dialysis units across the UK. Patients included in the study must be at least 18 years of age, receiving ESA therapy, and have serum ferritin levels < 400 mg/L and TSAT <30% at baseline. Key exclusion criteria are life expectancy of <12 months, scheduled transplant within 12 months, C-reactive protein levels > 50 mg/L, and presence of active infection or malignancy.
Study subjects are being randomized into two treatment arms: Those in the proactive IV iron arm will receive 400 mg of iron sucrose monthly provided that ferritin levels are <700 mg/L; iron dose will be withheld if ferritin levels are >700 mg/L and/or TSAT levels are >40%. Subjects in the reactive IV iron arm will receive 200 mg iron sucrose if serum ferritin levels are <100 mg/L, regardless of TSAT levels, and will receive 100 mg IV iron sucrose if ferritin levels are >100 mg/L, with TSAT <20%; iron will be withheld if ferritin levels are >200 mg/L and TSAT levels are >20% (Figure 1) .
The primary endpoint of the study is time to all-cause death or a composite of non-fatal CV events [myocardial infarction (MI), stroke or hospitalization for heart failure (HF)]. Secondary efficacy endpoints include: incidence of all-cause death and a composite of MI, stroke and hospitalization for HF as recurrent events; time to (and incidence of) all-cause death, composite CV event, MI, stroke, hospitalization for HF; ESA dose requirements; transfusion requirements; and patient functioning and QOL evaluated using the EuroQOL 5 dimensions questionnaire (EQ-5D) and the Kidney Disease Quality of Life (KDQOL) instrument. Secondary safety endpoints to be assessed are incidence of vascular access thrombosis, all-cause hospitalization, hospitalization for infection and infectious episodes, as well as incidence of SAEs, adverse drug reactions and suspected unexpected serious adverse reactions. Tertiary endpoints to be assessed include cumulative iron dose as well as haemoglobin, mean cell volume, red cell distribution width, ferritin, TSAT and platelet levels. The trial is event-driven and evaluation of outcomes will be conducted only once the required number of events are accrued (follow-up time of $2-4 years is expected). At the time of writing, all 2080 patients have been recruited and randomized to the trial, and follow-up is ongoing. It is expected that the results of this trial will not be available until 2018, but it is likely that the data from this trial will significantly impact future iron management in CKD patients.
Concluding remarks
Guidelines on iron management in CKD patients are somewhat dated, conflicting and based on sparse evidence. Two new RCTs in non-dialysis CKD patients (FIND-CKD and REVOKE) significantly improve the quality of the evidence base, but unfortunately produced conflicting results, which leaves us as confused as ever. Observational data are hypothesis-generating, but of limited clinical value due to significant confounding; moreover, the results of the new observational studies published since the 2012 KDIGO guideline are also conflicting. The PIVOTAL study seeks to fill the evidence gap, but results are not due until 2018.
